Lung Transplantation Clinical Trial
Official title:
Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)
The purpose of this study is to determine the optimal delivery system for the nebulization of the lipid complex amphotericin B (Abelcet ®) in lung transplant recipients who are positive for invasive aspergillosis (IA) in their lungs. Additionally, the investigators hope to determine the concentrations of amphotericin B achieved in the epithelial lining fluid, and serum with the administration of four days of lipid complex of amphotericin B (Abelcet ®) (QD) via aerosolized nebulization
Subject's visit for teaching and administration of the first dose of aerosolized liposomal
Amphotericin will be performed at the specified intervals before the scheduled bronchoscopy.
Subject will receive first dose of the aerosolized liposomal amphotericin under direct
supervision of physician and study coordinator. This visit will last approximately 2 hours.
Subject's spirometry will be performed before (standard of care) and after the
administration (research related) of first dose aerosolized liposomal amphotericin. Each
spirometry measurement takes approximately 1 hour. Prior to administration, blood pressure
and heart rate will be obtained.
In the absence of any significant side effect of the aerosolized liposomal amphotericin
(e.g., wheezing, shortness of breath, drop in FEV1 > 15%, the remaining three doses will be
dispensed to the patient through pharmacy. The subject will be instructed on how to measure
his/her peak flow rate before and after taking the aerosolized liposomal amphotericin.
(approximately 1 hour) A 24 hr study pager number will be given to subjects to contact the
investigators in case of development of side effects such as shortness of breath, wheezing,
heaviness in the chest.
The study coordinator will contact the subject daily to ensure the compliance with the
aerosolized liposomal amphotericin administration and monitor any untoward effects. This
phone contact will not take longer than 10 minutes of the participant's time.
Drug administration: Subjects will be dispensed vials of ABELCET ® and will be taught by the
study coordinator/investigators to draw drug from the vial to nebulizer. Detailed written
instructions will also be provided to the subjects. In addition subjects will prove the
comprehension of the instructions by demonstrating the procedure, to the study coordinator
during initial visit. The description for the patient is as follows "Before administering
the drug via nebulization, shake the vial gently until there is no evidence of any yellow
sediment at the bottom. Withdraw the appropriate dose of ABELCET ® from the required number
of vials into one or more sterile syringes using an 18-gauge needle. Remove the needle from
each syringe filled with ABELCET ® and replace with the 5-micron filter needle supplied with
each vial. Put no more than 7 ml of ABELCET ® in the nebulizer and inhaled over a period of
15 minutes. Continue the inhalation process until whole the amount is used up. Repeat the
procedure with additional drug if your doctor has prescribed more drug for you". Aero
Eclipse Nebulizer and Devilbliss 8650D compressor will be used for the study.
;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02581111 -
Naloxone for Optimizing Hypoxemia Of Lung Donors
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02177916 -
Patient Education Study to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation
|
N/A | |
| Not yet recruiting |
NCT01394835 -
Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients
|
Phase 2 | |
| Completed |
NCT01204970 -
Confocal Laser Micro-endoscopy in Chronic Obstructive Pulmonary Disease (COPD) and Lung Transplant Recipients
|
N/A | |
| Not yet recruiting |
NCT01162148 -
Pulmonary Rehabilitation and Inspiratory Muscle Training (IMT) for Patients Following Lung Transplantation
|
N/A | |
| Active, not recruiting |
NCT00980967 -
Predictive Factors for Chronic Rejection in Lung Transplant Recipients: COLT Study
|
N/A | |
| Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
| Recruiting |
NCT00163696 -
Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease
|
N/A | |
| Completed |
NCT00163891 -
Comparison of Two Chest Physiotherapy Protocols in Lung Transplant Recipients
|
N/A | |
| Completed |
NCT03668483 -
Relation Between Muscle Strength With Exercise Capacity and Dyspnea in LTx
|
N/A | |
| Not yet recruiting |
NCT02855372 -
Impact of the Age Difference Between the Donor and Recipient on the Morbidity and Mortality After Lung Transplantation. Study on a National Multicenter Cohort (COLT)
|
N/A | |
| Completed |
NCT01212406 -
Vitamin D in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
| Completed |
NCT01211509 -
Montelukast in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
| Not yet recruiting |
NCT00808600 -
Empowerment of Lung and Heart-lung Transplant Patients
|
N/A | |
| Completed |
NCT00553397 -
Live Lung Donor Retrospective Study
|
N/A | |
| Completed |
NCT00402805 -
Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy
|
Phase 4 | |
| Completed |
NCT00701922 -
Surveillance Study of Viral Infections Following Lung Transplantation
|
N/A | |
| Terminated |
NCT00235651 -
Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients
|
Phase 3 | |
| Active, not recruiting |
NCT02936505 -
Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.
|
N/A | |
| Recruiting |
NCT03798860 -
Monitoring of Donor-specific Antibodies After Treatment With Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation
|